COMP <GO>
VCYT vs ABBV // REVENUE GROWTH (YOY)
Veracyte Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: VCYT 6
— ABBV 9
▲ REVENUE GROWTH (YOY) LEADER: VCYT
LAST: $50.01 (-4.14%) • MKT CAP: $4.19B
revenue-growth
16.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCYT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCYT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.10% | 70.20% | -0.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 29.00% | -24.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 58.7x | 33.3x | +25.40 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 3.02% | 3.47% | -0.45 | ABBV | /fcf-yield <GO> |
| Operating Margin | 11.20% | 24.60% | -13.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 12.80% | 6.90% | +5.90 | VCYT | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 16.00% | 8.60% | +7.40 | VCYT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | VCYT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | VCYT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | VCYT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.9 | 72.8 | -11.86 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 53.1x | 113.1x | -60.00 | VCYT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.19B | $513.86B | -$509.67B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCYT REV | ABBV REV | VCYT GROSS % | ABBV GROSS % | VCYT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $517.1M | $61.16B | 70.1% | 70.2% | $126.6M | $17.82B |
| FY 2024 | $445.8M | $56.33B | 66.9% | 70.0% | $63.8M | $17.83B |
| FY 2023 | $361.1M | $54.32B | 44.0% | 44.0% | $28.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCYT // BETA 1.08
ABBV // BETA 1.15